Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences, Inc. (XBIO)
:XBIO
XBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $5.27
Previous CloseN/A
Volume4.73K
Average Volume (3M)27.01K
Market Cap
$4.78M
Enterprise Value$1.27M
Total Cash (Recent Filing)$5.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 14, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding1,542,139
10 Day Avg. Volume12,873
30 Day Avg. Volume27,011
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue0.49
Enterprise Value/Gross Profit0.49
Enterprise Value/Ebitda-0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of patient dosing in the exploratory study of DNase I for advanced pancreatic cancer marks a significant step forward in its clinical development.
CollaborationsThe collaboration with PeriNess Ltd. supports the clinical study of DNase I in combination with anti-CD19 CAR T cells, showcasing Xenetic's commitment to advancing its oncology platform.
Preclinical StudiesPreclinical studies indicate that DNase I, when combined with CAR-T therapy, significantly suppresses metastatic tumor burden and prolongs survival in murine models.
Bears Say
Financial PerformanceXenetic announced 1Q25 financial results, posting EPS of ($0.59) compared to an estimate of ($0.72).
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences, Inc.’s price range in the past 12 months?
Xenetic Biosciences, Inc. lowest stock price was $2.20 and its highest was $5.27 in the past 12 months.
What is Xenetic Biosciences, Inc.’s market cap?
Xenetic Biosciences, Inc.’s market cap is $4.78M.
When is Xenetic Biosciences, Inc.’s upcoming earnings report date?
Xenetic Biosciences, Inc.’s upcoming earnings report date is Nov 14, 2025 which is in 62 days.
How were Xenetic Biosciences, Inc.’s earnings last quarter?
Xenetic Biosciences, Inc. released its earnings results on Aug 08, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.19.
Is Xenetic Biosciences, Inc. overvalued?
According to Wall Street analysts Xenetic Biosciences, Inc.’s price is currently Overvalued.
Does Xenetic Biosciences, Inc. pay dividends?
Xenetic Biosciences, Inc. does not currently pay dividends.
What is Xenetic Biosciences, Inc.’s EPS estimate?
Xenetic Biosciences, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Xenetic Biosciences, Inc. have?
Xenetic Biosciences, Inc. has 1,542,139 shares outstanding.
What happened to Xenetic Biosciences, Inc.’s price movement after its last earnings report?
Xenetic Biosciences, Inc. reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went down -6.734%.
Which hedge fund is a major shareholder of Xenetic Biosciences, Inc.?
Currently, no hedge funds are holding shares in XBIO
Company Description
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. (XBIO) is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. The company primarily operates in the field of oncology, leveraging its proprietary technologies to advance its drug development pipeline. Xenetic is known for its platform technologies that enhance the efficacy and safety profiles of biologic drugs, particularly in the treatment of cancer.
XBIO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Kazia Therapeutics
―
Theriva Biologics
―
Jaguar Animal Health
―
Oragenics
―
Pasithea Therapeutics Corp
―
Ownership Overview
―
Insiders
1.30% Mutual Funds
1.88% Other Institutional Investors
96.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---